--- title: "Execution Over Protection: Looking Beyond the Licensing-First Approach" module: day1 order: 2 duration: prework: 35 session: 60 challenge: 45 tags: [strategy, competitive-advantage, execution, licensing, business-models] teaser: "IP protection feels like the responsible move. But most businesses that win, win through execution, and protecting too early can actually slow you down. The truth is messier than either camp admits." gated: false components: [] overview: objectives: - "Account honestly for what IP protection costs an early venture in time, disclosure, capital, rigidity, and culture" - "Recognise execution moats: customer knowledge, speed, relationships, tacit expertise, and revenue" - "Identify the market structures (pharma, licensed content, easy replication) where protection is the model, not an option" - "Form a tentative protect-first or execute-first position for your own field, and know what it depends on" prework: "About 35 minutes: the core execution-over-protection argument, a two-sided cost ledger, and eight deliberately conflicting cases, from Basecamp, Moderna, Spotify, and CRISPR to Napster, Dyson, the Lipitor patent cliff, and Amazon one-click." session: "A 60-minute structured argument: the copycat test on your own work, cost accounting with real magnitudes, why your customer does not care who owns the patent, and what the conflicting cases reveal about your situation." challenge: "A 45-minute Moat Map: list what a competitor would actually need to replicate you, sort your strongest moat candidates, face the honest trade-offs, and write the one-paragraph moat argument an investor would ask for." --- ## Pre-Work (~35 minutes) *Read this before the session. The discussions will go deeper if you arrive with a position, even a tentative one.* --- ### The Core Argument Here is the claim this lesson asks you to test: > **For most research-based ventures, IP protection adds less competitive value than the time, money, and energy it costs, and a relentless focus on execution will build a more durable business faster.** That claim is not always true. The session is designed to find the edges where it breaks down. But it is true more often than researchers expect. The default assumption in academic institutions: "protect first, then commercialise", reflects the incentives of technology transfer offices and IP lawyers more than it reflects the realities of building a business. Those incentives are real and legitimate. They just aren't your incentives. --- ### What Protection Costs You The costs of IP protection are visible on an invoice. The costs it imposes on your *business* are less obvious. **Time.** A patent application takes 2–4 years to grant. During that window you may be legally restricted from disclosing the full details of your approach to potential customers, partners, or collaborators. Every month you're protecting is a month a competitor who chose not to protect is talking to customers, iterating, and learning. **Disclosure.** Patents require full public disclosure of your invention. Once filed, your approach is visible to any competitor who searches the literature, often before you've reached the market. The secrecy that provisional patents offer expires. Protection eventually means revealing. **Capital.** International patent portfolios cost $15,000–$50,000+ to file, and require ongoing maintenance fees in each jurisdiction. For an early-stage venture with limited runway, that capital is not going toward product development, customer discovery, or hiring. **Rigidity.** Patents protect a specific implementation. If the market tells you your approach needs to change, and it usually does, you may be protecting the wrong thing. Execution-first organisations can pivot. Patent-first organisations are anchored to what they filed. **Culture.** NDAs, secrecy protocols, and IP restrictions create friction in research environments built on openness and collaboration. They can damage relationships with the academic ecosystem that produced your innovation in the first place. --- ### What Execution Gains You Execution-first organisations invest the same time and money in a different set of advantages: **Customer knowledge.** Every week you're talking to customers instead of filing paperwork is a week of learning. Who actually needs this? What are they willing to pay? What's the workflow it fits into? This knowledge is tacit, personal, and genuinely hard for competitors to replicate. **Speed to market.** First-mover advantage is real, though often overstated. What is reliably real is the compounding effect of getting feedback earlier. Organisations that ship faster improve faster. **Relationships.** The customers, collaborators, and distribution partners you build relationships with early create genuine switching costs, not because of contracts, but because of trust, history, and integration. A competitor with a better product may still lose to you because your customers don't want to retrain their staff and risk a transition. **Tacit knowledge.** The deep, embodied expertise your team accumulates through doing, the failures that don't appear in any paper, the workarounds that took six months to find, is genuinely difficult to replicate. It doesn't appear in a patent application. It lives in people. **Revenue.** Revenue funds the next iteration. A business generating $200K/year from early customers is more defensible than a business with a pending patent and no revenue. --- ### What Protection Gains You To argue fairly: here is what IP protection genuinely does well. **Legal standing.** A patent gives you the same legal standing as a multinational corporation when defending against infringement. Without it, a well-funded competitor can replicate your approach and you have little recourse. **Licensing income.** In some industries, the most economically rational path is not to build a business but to license your invention. Pharmaceutical compounds, certain semiconductor designs, and materials innovations often have more value as licences than as ventures. If this is your model, protection isn't optional, it is the model. **Investor confidence.** Many investors, particularly in life sciences and deep tech, require a defensible IP portfolio before they will write a cheque. The patent is not evidence of business viability; it is a signal that the underlying science has been validated and disclosed. In capital-intensive industries, this signal matters. **Freedom to operate.** Knowing what you own, and what competitors own, lets you navigate the patent landscape without accidental infringement. A freedom-to-operate analysis is valuable even if you never file a patent yourself. **Deterrence.** A portfolio of patents can deter competitors from entering your space, even if you never intend to litigate. The threat of expensive litigation is often enough. --- ### What Execution Costs You The honest account also includes what execution-first organisations give up. **Copycat vulnerability.** If your innovation is easy to replicate, a software feature, a process improvement, a formulation, a well-funded competitor can build it in a fraction of the time it took you, without bearing your R&D costs. In markets where replication is cheap, protection matters more. **Platform risk.** For software and digital tools, large platform companies can replicate your functionality and distribute it to their installed base in a product update. Execution moats can be erased by incumbents with distribution advantages. This is a structural risk that no amount of execution can fully mitigate without some form of protection or platform lock-in. **Capital access.** As noted above, some investors simply will not invest without IP. If your path requires venture capital, and your investors require patents, execution-first is not a strategy, it is a disqualifier. **Pharma is different.** In pharmaceutical development, the economics of clinical trials are so extreme, hundreds of millions of dollars, a decade of development, that no company would invest without the monopoly pricing that patent protection enables. Execution without protection in drug development is not a viable model. It is not even a coherent one. --- ### Four Case Studies These cases are deliberately in tension. Read all four and come to the session prepared to argue about them. --- #### Case Study 1: Basecamp: The Execution Purist 37signals (now Basecamp) built project management software in 2004 with essentially no IP protection. They wrote blog posts, published books, and shared their methodology openly, including the business philosophy behind their product. They told competitors exactly how they built things. By 2020 they had approximately 100,000 customers and tens of millions in annual revenue with fewer than 60 employees. In a market crowded with better-funded competitors, Asana, Monday.com, Trello, Jira, they remained profitable and independent. Their moat was never a patent. It was an aesthetic, a philosophy, and a customer relationship. Competitors could read every word they published and still not replicate the specific culture, taste, and decision-making that made the product coherent. **What made this work:** software, a small and targeted market, a strong product philosophy, direct sales. The product itself was the marketing. **Where this breaks down:** Basecamp operates in a low-capital-expenditure market. Their "moat" requires a team with unusual taste and discipline. It is not transferable. Most people who try to copy their model don't have the cultural raw material to execute it. --- #### Case Study 2: Moderna vs. Pfizer/BioNTech: When Patents Are Existential In 2022, Moderna sued Pfizer and BioNTech for infringing patents on mRNA vaccine technology. Moderna claimed Pfizer's COVID-19 vaccine used modifications to mRNA that Moderna had invented and patented before the pandemic. The stakes: billions of dollars in royalties, potential injunctions against vaccine manufacturing, and the precedent for who owns the foundational IP layer of what may be the most important vaccine platform in decades. This is not a case where execution could substitute for protection. The capital required to develop an mRNA therapeutic, years of pre-clinical research, Phase I/II/III trials, regulatory approval, manufacturing scale-up, is only recoverable through pricing power that patents enable. Without exclusivity, a generic manufacturer could produce the same vaccine at cost the day after approval. The business model collapses. **What made protection essential:** extreme capital requirements, commodity manufacturing once the formulation is known, regulatory pathway as the primary value gate, pricing power as the only cost-recovery mechanism. **Where this breaks down:** Moderna's patents didn't prevent competition, they invited expensive litigation and generated enormous reputational risk during a public health crisis. The public perception of profiting from a pandemic-era patent has long-term brand consequences that execution-first companies rarely face. --- #### Case Study 3: Spotify: Execution on Someone Else's IP Spotify built one of the most successful consumer technology companies of the past two decades without owning any of the content it delivers. Every song on the platform is licensed from rights holders. Spotify's entire business model is built on top of other people's IP. Their competitive advantage was never the music. It was the discovery engine, the social graph, the interface, the playlist culture, and the frictionless experience of having almost everything in one place. They executed brilliantly on a product layer built on a licensed foundation. And yet: Spotify has never been particularly profitable. The royalty obligations that enable their existence also compress their margins structurally. Apple Music, Amazon Music, and YouTube Music have distribution advantages that no amount of execution can fully overcome, they can afford to lose money on music indefinitely because music is one feature in a larger ecosystem. **What made this work:** massive consumer market, high switching costs through playlists and recommendations, first-mover network effects in playlist culture, and superior UX at launch. **Where this breaks down:** executing on licensed IP in a market with platform incumbents creates a structural ceiling. Spotify's future depends on moving up the stack, into podcasts, audiobooks, tools for artists, to find margins that music licensing won't provide. Execution alone, without owned IP or platform control, has limits. --- #### Case Study 4: The CRISPR Patent War: Science, Priority, and Billions Jennifer Doudna at UC Berkeley and Feng Zhang at the Broad Institute independently developed key elements of CRISPR-Cas9 gene editing within months of each other. Both institutions filed patents. The dispute over who invented what, and who filed first, consumed years of legal process and tens of millions in legal fees. The outcome matters because CRISPR licences are worth enormous sums. Whoever controls the foundational patents controls the licensing revenue from every therapeutic, agricultural, and industrial application of the technology. In this case, both institutions eventually secured rights to different application domains. But here is the question the case raises: **what happened to the science while the lawyers argued?** Researchers continued to publish, iterate, and build applications of CRISPR through the entire dispute. The patent battle affected the business layer, who could commercialise, on what terms, but had essentially no effect on the scientific progress. The execution of the research was entirely decoupled from the IP dispute. **What this shows:** patent disputes are expensive, slow, and largely fought at the institutional rather than the researcher level. The researchers who did the science mostly kept working. The question of who owned the IP was a question for technology transfer offices and law firms, not for the people doing the actual work. --- ### Counter-Examples: When the Execution Argument Fails The case for execution-first is strong. It is not universal. Four shorter cases, chosen specifically because they challenge the lesson's main argument: **Napster vs. Spotify.** Napster hit 80 million users in 18 months, the fastest consumer tech adoption of its era, and was shut down in 2001 anyway: not for poor execution, but because it had no legal right to distribute the music it distributed. Spotify launched with the same value proposition but spent two years pre-launch securing licences before building a user base. **What this shows:** execution without a legal right to operate is not a moat, it's a liability. Where your core input is owned by someone else (music, pharmaceutical compounds, proprietary datasets), IP isn't optional, it's the ante. **Dyson.** James Dyson filed patents on his cyclone vacuum in the early 1980s after three years of prototyping, then spent nearly two decades in licensing disputes with copycats. The patents didn't stop copying forever, but they bought the years he needed to build the brand and distribution that became the real moat. **What this shows:** execution moats take years to compound; protection can be the thing that buys you that time rather than something in competition with it. **The Lipitor patent cliff.** When Pfizer's best-selling drug lost patent protection in 2011, revenue dropped roughly 70% within a year, not from poor execution, but because generics could now produce an identical compound at a fraction of the cost. **What this shows:** execution moats don't survive markets where the product can be exactly replicated. The question isn't "can they copy me today?" but "can they copy me in five years, when I need the business to still be viable?" **Amazon's one-click patent.** Widely mocked as trivial when filed in 1999, it blocked Barnes & Noble from a similar checkout for years and forced Apple to pay for a licence, during the exact window when checkout friction most affected purchase decisions. **What this shows:** even in software, a precisely targeted patent at the right moment can matter. Most software patents don't; the question is whether yours is in the minority that does. --- ### Reflection Prompts Bring your thinking on these to the session. There are no right answers. 1. Which of the four case studies most closely resembles your field, not your specific work, but the structural economics of your research area? Why? 2. If a well-funded competitor started working on something similar to your current research today, what would they actually need to replicate you? How long would it take? 3. Is there something you're currently keeping confidential that might be more valuable if it were public? What's the argument for and against disclosure? ```lms type: reflection_response id: execution-over-protection-prework-reflection prompt: "Answer one or all three prompts above before the session." min_words: 40 ``` --- ## Session *Facilitator guide. 60 minutes. Participants should have read all four case studies.* --- ### Before You Begin This session works best when participants disagree with each other. If the room quickly converges on "execution is better," push back. If they converge on "protection is always necessary," push back the other way. The nuance is the point. Have the four case study names visible on a whiteboard or slide throughout: Basecamp · Moderna · Spotify · CRISPR. --- ### Discussion 1: The Copycat Test (10 min) *Pairs. Purpose: make the threat model concrete before discussing the response.* Prompt: > **Imagine someone in your field, a well-funded competitor, a large company, or a foreign government-backed research programme, decided today to replicate your work. What would they actually need?** Push participants to be specific: people, equipment, data, time, relationships, institutional access. Then ask: of those things, which ones can a patent prevent them from acquiring? Share-back: one person per pair names the thing on their list that surprised them most. --- ### Discussion 2: The Cost Accounting Argument (10 min) *Small groups of 3–4. Purpose: challenge the assumption that protection is "responsible" and execution is "risky."* Prompt: > **Basecamp chose not to protect. Moderna had to protect. Spotify built on licensed IP. CRISPR forced protection through institutional incentives.** > > **For your research area: what does protecting cost you, and what does it cost you to skip it? Be specific about both sides of the ledger.** Facilitator note: push groups to assign rough magnitudes. "$30K in filing costs vs. six months of a competitor's head start" is more useful than abstract lists. ```lms type: session_response id: execution-over-protection-session-cost-accounting prompt: "For your research area: what does protecting cost you, and what does it cost you to skip it? Assign rough magnitudes to both sides." min_words: 40 ``` Share-back: one cost from each side of the ledger, per group. --- ### Discussion 3: The Customer Doesn't Care (15 min) *Plenary. This is often the most disorienting discussion for researchers. Take time here.* Open with: **"Does your customer care who owns the patent?"** In most markets, the answer is no. Customers care whether the product works, whether it integrates with their workflow, whether the team will support them, and whether the price is fair. The patent is invisible to them. There are exceptions: regulated markets where IP status affects approval pathways, procurement processes that require IP indemnification, and markets where brand trust is built on innovation credentials. Name these explicitly and ask whether they apply. Then push to the sharper question: **"What does your customer actually value that a competitor would struggle to replicate, not because of a patent, but because of what it would require them to do?"** This is where execution moats show up: a team that understands the biology at a level competitors don't yet have, a dataset that took five years to assemble, a clinical relationship network built on trust, a workflow integration that would require months of redevelopment. Close with: **"If you were advising a first-time founder in your field, what would you tell them to invest in first, protection or execution? What would make you change that advice?"** --- ### Discussion 4: The Conflicting Cases (15 min) *Assign each small group one case study pair, Basecamp vs. Moderna, or Spotify vs. CRISPR. Ask them to argue both sides.* Prompt: > **Your case study pair represents two different answers to the same question. What structural features of each business made one approach right and the other wrong? Could either company have chosen the other path?** This is the analytical core of the session. What participants should find: the right approach is not a philosophy but a function of capital requirements, replication cost, customer structure, and market dynamics. Basecamp could not have chosen Moderna's path even if it had wanted to, and vice versa. ```lms type: session_response id: execution-over-protection-session-conflicting-cases prompt: "What structural features of your assigned case pair made one approach right and the other wrong? Could either company have chosen the other path?" min_words: 40 ``` Share-back: one structural factor per group that most clearly explained the divergence. --- ### Discussion 5: Your Honest Assessment (10 min) *Return to plenary. This connects the theory back to each participant's actual situation.* Ask each participant to answer out loud or in a shared doc: **"Based on this session, am I in a situation where protecting first makes structural sense, or where executing first is the better bet? What's the one piece of evidence that most influenced that answer?"** Facilitator: don't let participants say "it depends" without specifying what it depends on. The goal is a tentative position, not a final answer. ```lms type: session_response id: execution-over-protection-session-honest-assessment prompt: "Are you in a situation where protecting first makes structural sense, or where executing first is the better bet? What's the one piece of evidence that most influenced that answer?" min_words: 40 ``` Close: *"Your challenge this week asks you to write the moat argument, the honest account of what actually protects your work, whether or not it's a patent. That's the document an investor, a partner, or a competitor would want to understand. Writing it for yourself is the first step."* --- ## Challenge (~45 min) *Produce something you can use. This feeds into mentoring check-ins and 90-day planning.* --- ### Your Moat Map Work through this for one piece of research, technology, or expertise you're actively developing. **Part 1, The Replication Analysis** List everything a well-funded competitor would need to replicate your work: - Scientific or technical knowledge - Equipment or infrastructure - Data, samples, or proprietary materials - Relationships (clinical, industrial, regulatory) - People and tacit expertise - Time For each item, estimate: how long would it take them to acquire it, and how much would it cost? Mark each one: *easy to replicate* / *hard to replicate* / *essentially irreplicable*. ```lms type: challenge_prompt id: execution-over-protection-challenge-1 prompt: "The Replication Analysis: list what a well-funded competitor would need to replicate your work, and mark each item easy to replicate / hard to replicate / essentially irreplicable." min_words: 80 ``` **Part 2, The Moat Candidates** From your list, identify the 2–3 things that are hardest to replicate. For each, decide which category it falls into: - **IP-based**: protected by a patent, trade secret, or copyright - **Execution-based**: the result of accumulated doing: speed, iteration, tacit knowledge - **Relationship-based**: trust, access, and history that takes years to build - **Structural**: first-mover network effects, switching costs, platform position ```lms type: challenge_prompt id: execution-over-protection-challenge-2 prompt: "The Moat Candidates: name your 2-3 hardest-to-replicate items and which category (IP-based, execution-based, relationship-based, structural) each falls into." min_words: 60 ``` **Part 3, The Honest Trade-off** Answer these directly: 1. If you spent the next $30,000 on patent filing instead of product development, customer discovery, or hiring, would your competitive position be stronger or weaker in 18 months? 2. What is the thing you're most tempted to protect that you should probably just publish or open source? What's stopping you? 3. What is the thing you're most tempted to leave unprotected that probably needs protecting? What's stopping you? ```lms type: challenge_prompt id: execution-over-protection-challenge-3 prompt: "The Honest Trade-off: answer the three questions above about the $30,000 test, what you're tempted to over-protect, and what you're tempted to under-protect." min_words: 60 ``` **Part 4, The Moat Argument** Write one paragraph, 100–150 words, as if you're answering the question an investor just asked: *"What stops a well-resourced competitor from copying you?"* Do not mention patents unless patents are genuinely your answer. If your moat is execution, say so. If it's relationships, say so. If you don't have a convincing moat yet, say that too, that's an honest and useful starting point. ```lms type: challenge_prompt id: execution-over-protection-challenge-4 prompt: "The Moat Argument: write the 100-150 word paragraph answering 'what stops a well-resourced competitor from copying you?'" min_words: 100 ``` Bring this to your next mentoring check-in. --- ## Key Concepts Reference **Execution moat**: competitive advantage derived from superior speed, quality, iteration, or accumulated know-how rather than legal protection. Often more durable than IP in fast-moving markets; more fragile in capital-intensive ones. **Replication cost**: how much time and money a competitor would need to reproduce your capability. High replication cost is a genuine moat regardless of patent status. **Tacit knowledge**: knowledge embedded in people and practice that cannot be fully written down or transferred through documentation. The accumulated expertise of a team that has done something for years is often the hardest thing for a competitor to replicate. **Switching costs**: the friction a customer faces when moving from your product to a competitor's. Can be technical (integrations, data formats), relational (trust, training, history), or contractual. **Platform risk**: the vulnerability of a product that competes inside a platform controlled by a larger player. The platform owner can replicate your features at near-zero marginal cost and distribute them to their user base in a product update. **Freedom to operate (FTO)**: an analysis of whether you can build and sell your product without infringing existing patents. Useful even if you never file a patent of your own. **Licensing model**: a business model in which value is captured through charging others for the right to use your IP, rather than through building and selling a product or service. Requires strong IP protection; often more appropriate in capital-intensive industries than in software or services.